跳至主要内容
临床试验/EUCTR2012-000026-22-ES
EUCTR2012-000026-22-ES进行中(未招募)1 期

Open, Observer-blind, two Parallel Group, Randomized, Multicentric Clinical Phase III Trial on the Comparison of Efficacy and Tolerability of a New Preservative-free Formulation of Travoprost 40 µg/ml Eye Drops vs. Travatan? Eye Drops in Patients with Primary Open Angle Glaucoma or Ocular Hypertension - QTM/OMN0112

Omnivision GmbH0 个研究点目标入组 0 人开始时间: 2012年2月3日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • ?male or female patients, of any race and ?18 years of age;
  • ?diagnosed of unilateral or bilateral primary open angle glaucoma or ocular hypertension;
  • ?on treatment with an IOP-lowering prostaglandin analogue for at least 6 months;
  • ?on treatment with an IOP ?21 mmHg on medication measured as a mean of both eyes at two measurements at least one hour apart;
  • ?best-corrected visual acuity ?20 of 100 corresponding to logMAR of 0.7 in both eyes;
  • ?in case of women, postmenopausal (>12 months without menstrual bleeding), surgically sterilized, or on use of effective birth control measures;
  • ?expected by the investigator that IOP would remain controlled with the new treatment without optic nerve damage or progression of visual field loss;
  • ?able to understand the requirements of the clinical trial and to agree to return for required follow-up visits;
  • ?willing to provide voluntary written informed consent and data protection declaration before any clinical trial related procedure is performed.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 170
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • ?pre-treatment for primary open angle glaucoma or intraocular hypertension other than prostaglandin analogues;
  • ?a history of chronic or recurrent inflammatory eye disease, ocular trauma or infections;
  • ?narrow-angle/angle-closure glaucoma;
  • ?clinically significant or progressive retinal disease;
  • ?intraocular surgery within the past 6 months;
  • ?ocular laser surgery within the past 3 months;
  • ?a change in glaucoma therapy within 1 month before the screening visit;
  • ?best-corrected visual acuity worse than 0.7 logarithm of minimal angle of resolution (logMAR) score, extremely narrow or partially closed angle, cup/disk ratio >0.8;
  • ?history of bronchial asthma, or severe chronic obstructive pulmonary disease; reactive airway disease including bronchial asthma, a history of bronchial asthma, or severe chronic obstructive pulmonary disease.
  • ?treatment with local or systemic corticosteroids;
  • ?inability to discontinue the use of glucocorticoid medications;
  • ?not receiving stable doses of any medication that could affect IOP for 30 days before the beginning of the clinical trial (e.g. clonidine);

研究者

相似试验

进行中(未招募)
不适用
Open, Observer-blind, two Parallel Group, Randomized, Multicentric Clinical Phase III Trial on the Comparison of Efficacy and Tolerability of a New Preservative-free Formulation of the Fixed Combination Latanoprost 50 µg/ml and Timolol 5 mg/ml Eye Drops vs. Xalacom? Eye Drops in Patients with Primary Open Angle Glaucoma or Ocular HypertensioPrimary open angle glaucoma or intraocular hypertensionMedDRA version: 14.0Level: PTClassification code 10030043Term: Ocular hypertensionSystem Organ Class: 10015919 - Eye disordersMedDRA version: 14.0Level: LLTClassification code 10036719Term: Primary open angle glaucomaSystem Organ Class: 10015919 - Eye disorders
EUCTR2011-005339-15-ESOmnivision GmbH
进行中(未招募)
不适用
This study will evaluate and confirm that the efficacy and tolerability of a New Preservative-free Formulation of Brimonidine 2 mg/ml Eye Drops is not worse compared to the marketed preservative-containing formulation Alphagan™ Eye Drops in Patients with Open Angle Glaucoma or Ocular HypertensioOpen angle glaucoma or ocular hypertension.MedDRA version: 14.1Level: PTClassification code 10030043Term: Ocular hypertensionSystem Organ Class: 10015919 - Eye disordersMedDRA version: 14.1Level: PTClassification code 10030348Term: Open angle glaucomaSystem Organ Class: 10015919 - Eye disorders
EUCTR2013-003083-31-GROmniVision GmbH
进行中(未招募)
1 期
Open, Observer-blind, two Parallel Group, Randomized, Multicentric Clinical Phase III Trial on the Comparison of Efficacy and Tolerability of a New Preservative-free Formulation of the Fixed Combination Travoprost 40 µg/ml and Timolol 5 mg/ml Eye Drops vs. DuoTrav? Eye Drops in Patients with Primary Open Angle Glaucoma or Ocular HypertensioOpen Angle Glaucoma or Ocular HypertensionMedDRA version: 18.0Level: HLGTClassification code 10018307Term: Glaucoma and ocular hypertensionSystem Organ Class: 10015919 - Eye disordersMedDRA version: 18.0Level: PTClassification code 10030348Term: Open angle glaucomaSystem Organ Class: 10015919 - Eye disorders
EUCTR2012-000044-10-ESOMNIVISIO
进行中(未招募)
1 期
This study will evaluate and confirm that the efficacy and tolerability of the generic formulation Dorzo-Vision® sine Preservative-Free Eye Drops solution is not worse to the marketed preservative free formulation Trusopt® Eye Drops solution in Patients with Open Angle Glaucoma or Ocular Hypertension already on Treatment with IOP-lowering Drugs and Low Intraocular Pressure (IOP=21 mmHg)Open angle glaucoma or ocular hypertensionMedDRA version: 20.0Level: SOCClassification code 10015919Term: Eye disordersSystem Organ Class: 10015919 - Eye disordersMedDRA version: 20.0Level: PTClassification code 10030348Term: Open angle glaucomaSystem Organ Class: 10015919 - Eye disordersMedDRA version: 20.0Level: PTClassification code 10030043Term: Ocular hypertensionSystem Organ Class: 10015919 - Eye disorders
EUCTR2019-000913-35-GRBECRO (Cyprus) Ltd150
进行中(未招募)
1 期
Comparison of ADVAIR medication vs Salmeterol vs Albuterol in Asthma patients, assessing lung function and other measures of asthma control.Asthma
EUCTR2015-004865-10-Outside-EU/EEAGlaxoSmithKiline Research and Development LTD.547